CKD-357

CKD-357 is an investigational pharmaceutical drug developed by Chong Kun Dang Pharmaceutical. It has been studied in a randomized, open-label, single-dose, crossover clinical trial to evaluate its pharmacokinetic profile and safety/tolerability in healthy volunteers. The study compared CKD-357 with D578 (ticagrelor), suggesting that CKD-357 may be a formulation or generic version of ticagrelor, an antiplatelet agent commonly used for the prevention of thrombotic events in acute coronary syndrome. The primary outcomes measured were the area under the plasma concentration-time curve (AUC) and maximum plasma concentration (Cmax) of ticagrelor[6][1]. No additional brand names or alternative designations are reported.